Zhu et al. found that Nrf2 stimulates PD-L1 transcription, and targeted Nrf2 inhibition is an alternative way of suppressing PD-1/PD-L1 to trigger tumor infiltration by CD4+ and CD8+ T lymphocytes and consequentially restrict melanoma growth [34]. The gene discussed is CD8A; the disease is melanoma.